

Salon A

<b>08:45 – 09:00</b>	<b>Açılış</b>
<b>09:00 – 10:20</b>	<b>RENAL CANCER</b> <b>Oturum Başkanları: Dr. Yaşar Bedük, Dr. Levent Türkeri</b>
09:00 – 09:30	<b>Optimal Patient Selection for Active Surveillance or Ablation of Small Renal Masses</b> Dr. Sinan Sözen
09:30 – 09:50	<b>Evolving Role and Limitations of Percutaneous Renal Mass Biopsy in the Management of Localized Renal Masses: Does the Tumor Heterogeneity Matter?</b> Dr. Güven Aslan
09:50 – 10:20	<b>Optimal Imaging for the Indeterminate Renal Mass: How to Determine What is Indeterminate?</b> Dr. Barış Bakır
<b>10:20 – 10:50</b>	<b>Kahve Molası</b>
<b>10:50 – 12:30</b>	<b>RENAL CANCER-II</b> <b>Oturum Başkanları: Dr. Süleyman Ataus, Dr. Cenk Yücel Bilen</b>
10:50 – 11:30	<b>Value of Lymph Node Dissection in the M0 and M1 Patient</b> Dr. Levent Türkeri
11:30 – 11:50	<b>Timing and Patient Selection for Cytoreductive Nephrectomy</b> Dr. Saadettin Eskiçorapçı
11:50 – 12:05	<b>Oncologic and Functional Follow-up after Renal Mass Treatment</b> Dr. Özgür Yayıoğlu
12:05 – 12:30	<b>Optimal Sequencing of First and Second Line Systemic Therapy in Metastatic Clear Cell Renal Cell Carcinoma</b> Dr. Sevil Bavbek
<b>12:30 – 13:30</b>	<b>Öğle Yemeği</b>
<b>13:30 – 15:15</b>	<b>RENAL CANCER- III</b> <b>Oturum Başkanları: Dr. Cemil Uygur, Dr. Ali Tekin</b>
13:30 – 13:55	<b>Tyrosine Kinase Inhibitorsfor Renal Cell Carcinoma: Past, Present and Future</b> Dr. Aziz Karaoğlu
13:55 – 14:30	<b>The Future of Immuno Oncology in Renal Cell Carcinoma</b> Dr. Sercan Aksoy
14:30 – 14:50	<b>Best of Journals: Renal Cell Cancer – Urooncologist Perspective</b> Dr. Ahmet Çağ Çal
14:50 – 15:15	<b>Best of Journals: Renal Cell Cancer – Medical Oncologist Perspective</b> Dr. Mert Başaran

15:15 – 15:30	<b>Neoadjuvant Chemotherapy: Use of Molecular Markers</b> Dr. Çağatay Arslan
<b>15:30 – 16:00</b>	<b>Kahve Molası</b>
<b>16:00 – 17:35</b>	<b>TESTIS-ADRENAL TUMORS</b> <b>Oturum Başkanları: Dr. Hakan Özkardeş, Dr. Barış Kuzgunbay</b>
16:00 – 16:20	<b>Management of Marker-Negative Stage IIA Testicular Cancer</b> Dr. Bülent Akdoğan
16:20 – 16:45	<b>Management of Metastatic Disease for Adrenocortical Carcinoma and Pheochromocytoma</b> Dr. Mutlu Doğan
16:45 – 17:15	<b>Surgical Management of Adrenal Tumors</b> Dr. Ömer Demir
17:15 – 17:35	<b>Endocrinologic Issues in Adrenocortical Carcinoma and Pheochromocytoma</b> Dr. Füsün Baloş Törüner

<b>08:00 – 10:10</b>	<b>PROSTATE CANCER</b> <b>Oturum Başkanları: Dr. Turgut Alkibay, Dr. Müge Akmansu</b>
08:00 – 08:15	<b>Adjuvant Radiotherapy and Chemotherapy in Node-Positive Disease</b> Dr. İlker Tinay
08:15 – 08:30	<b>Molecular Therapies in Bone Metastases</b> Dr. Gökhan Özyiğit
08:30 – 08:45	<b>Prostate Cancer: Reviewing The Literature – Medical Oncologist Perspective</b> Dr. Mustafa Erman
08:45 – 09:10	<b>From The Clinic to The Lab: Investigating Immune Responses to Immune Checkpoint Therapy in Patients with Prostate Cancer</b> Dr. Yüksel Ürün
09:10 – 09:45	<b>Best of Journals 2017: Prostate Cancer – Radiation Oncologists Perspective</b> Dr. Fazilet Öner Dinçbaş
09:45 – 10:10	<b>Neoadjuvant Intense Androgen Deprivation Therapy for Localized High Risk Prostate Cancer</b> Dr. Talha Müezzinoğlu
<b>10:10 – 10:40</b>	<b>Kahve Molası</b>
<b>10:40 – 13:05</b>	<b>UROTHELIAL CARCINOMA</b> <b>Oturum Başkanları: Dr. Can Öbek, Dr. Gökhan Toktaş</b>
10:40 – 11:20	<b>Best of Journals: Urothelial Carcinoma Urooncologist Perspective</b> Dr. Sümer Baltacı
11:20 – 11:40	<b>Use of Molecular Markers in Bladder Preservation Therapy</b> Dr. Aydın Mungan
11:40 – 12:00	<b>Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer</b> Dr. Deniz Yalman
12:00 – 12:30	<b>Immune Checkpoint Inhibitors in Urothelial Cancer: Which one and Why?</b> Dr. Yüksel Ürün
12:30 – 12:50	<b>Best of Journals: Urothelial Carcinoma: Medical Oncologist Perspective</b> Dr. Mehmet Akif Öztürk
12:50 – 13:20	<b>Akılcı İlaç Kullanımı</b> Dr. Sinan Sözen